Revive Therapeutics Ltd.
RVV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 54.01% | -18.96% | -112.84% | 3.40% | 49.59% |
| Total Depreciation and Amortization | -100.00% | -100.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -75.60% | 162.50% | 162.56% | -7.47% | -- |
| Change in Net Operating Assets | 187.41% | 96.87% | 99.27% | 119.64% | -123.44% |
| Cash from Operations | 76.07% | 6.71% | 52.26% | 23.93% | -0.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 32.64% | -107.37% | -2.11% | -2.11% |
| Issuance of Common Stock | -- | -- | -78.71% | -50.85% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -32.64% | 87.31% | 2.11% | 2.11% |
| Cash from Financing | -- | -- | -- | -50.69% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 76.07% | 0.76% | 52.26% | -82.42% | -0.57% |